PRIMAXIN IV 500 500 MG
IMIPENEM : 500 MG CILASTATIN (CILASTATIN SODIUM) : 500 MG · DIN 01911449 · MERCK CANADA INC
Health Canada status: CANCELLED POST MARKET
What is PRIMAXIN IV 500?
PRIMAXIN IV 500 500 MG contains IMIPENEM : 500 MG CILASTATIN (CILASTATIN SODIUM) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 01911449, held by MERCK CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 13-May-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PRIMAXIN IV 500 used for?
PRIMAXIN ® (imipenem and cilastatin sodium) may be indicated in the treatment of serious infections when caused by sensitive strains of bacteria. Patients have responded while under treatment with PRIMAXIN ® for single or mixed infections of the following body systems: Lower Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Gynecological Infections, Septicemia, Endocarditis caused by Staphylococcus aureus, Bone and Joint Infections, Skin Structure Infections. PRIMAXIN® is not indicated for the treatment of meningitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01911449 |
|---|---|
| Brand name | PRIMAXIN IV 500 |
| Generic / active ingredient | IMIPENEM : 500 MG CILASTATIN (CILASTATIN SODIUM) : 500 MG |
| Manufacturer | MERCK CANADA INC |
| Strength | 500 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01DH51 IMIPENEM AND CILASTATIN |
| AHFS class | 08:12.07.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 13-May-2009 |
| Original market date | 1991-12-31 00:00:00 |
How is it administered?
Adults: 1-2 g daily in divided doses every 6-8 hours. Max 4 g or 50 mg/kg/day. Administer by I.V. infusion over 20-60 minutes depending on dose. Adjust for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
The dry powder should be stored at 15 °C-30 °C.
How is it supplied?
250 mg imipenem equivalent and 250 mg cilastatin equivalent in vials. 500 mg imipenem equivalent and 500 mg cilastatin equivalent in vials. 250 mg imipenem equivalent and 250 mg cilastatin equivalent in ADD-Vantage * vials. 500 mg imipenem equivalent and 500 mg cilastatin equivalent in ADD-Vantage * vials.
Contraindications
Hypersensitivity to either component of this product.
Warnings and precautions
Caution in patients with allergies to beta-lactams. Risk of pseudomembranous colitis. CNS effects (seizures, confusion) reported, especially with renal impairment or CNS disorders.
What can be used instead?
Other Canadian products sharing ATC code J01DH51 IMIPENEM AND CILASTATIN. 2 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| IMIPENEM AND CILASTATIN FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02358344 |
| TARO-IMIPENEM-CILASTATIN | 500 MG | POWDER FOR SOLUTION | SUN PHARMA CANADA INC | MARKETED | DIN 02351706 |
| IMIPENEM AND CILASTATIN FOR INJECTION | 250 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02357429 |
| IMIPENEM AND CILASTATIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02357437 |
| IMIPENEM AND CILASTATIN FOR INJECTION USP | 250 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02358336 |
| IMIPENEM AND CILASTATIN FOR INJECTION, USP | 250 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | DIN 02441225 |
| IMIPENEM AND CILASTATIN FOR INJECTION, USP | 250 MG | POWDER FOR SOLUTION | METHAPHARM INC | CANCELLED PRE MARKET | DIN 02439840 |
| IMIPENEM AND CILASTATIN FOR INJECTION, USP | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | DIN 02441233 |
| IMIPENEM AND CILASTATIN FOR INJECTION, USP | 500 MG | POWDER FOR SOLUTION | METHAPHARM INC | CANCELLED PRE MARKET | DIN 02439859 |
| PRIMAXIN 250 | 250 MG | POWDER FOR SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 00717274 |
Who else supplies IMIPENEM AND CILASTATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IMIPENEM AND CILASTATIN appears in 12 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.